Content continues after advertisement

Research Note: Once-Monthly Treatment for Feline Diabetes

Sign in to Print/View PDF

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as exenatide show promise in the treatment of feline diabetes. GLP-1RAs stimulate insulin secretion by pancreatic β cells in the presence of high glucose levels. The investigators in this study developed a delivery system that allowed the slow release of a stable GLP-1RA analog, [Gln28]exenatide. The study first validated the pharmacokinetics and pharmacodynamics of exenatide vs [Gln128]exenatide in cats, after which the conjugate compound consisting of [Gln28]exenatide bonded to hydrogel microspheres was evaluated. The plasma half-life of the SC administered microsphere-[Gln28]exenatide conjugate was ≈40 days as compared with 40 minutes with the injected free peptide. The investigators concluded that GLP-1RA in this formulation is suitable for once-monthly SC administration in cats.

Source

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy